Alphageneron will attend the ROTH Virtual Healthcare Private Company Forum on June 28, 2021



CAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) – Alphageneron Pharmaceuticals, Inc. (“Alphageneron” or the “Company”), a private clinical-stage biopharmaceutical company that develops autologous and allogeneic Natural Killer (NK) cells and antibodies Therapeutics announced that Robert Brooks, JD, Founder and CEO of Alphageneron, will attend the ROTH Healthcare Private Company Forum to be held virtually on Monday, June 28, 2021.

Alphageneron CEO Robert Brooks will speak on the Cancer Panel 2, entitled “Natural killer cell approaches to eradicate tumors, ”As one of the companies presenting on the panel with“ proof of concept ”data using NK cells against solid tumors. Mr Brooks will discuss a previously completed Phase IIa clinical trial with patients with advanced non-small lung cancer (NSCLC), receiving autologous Hsp70-targeted NK cell therapy (ENKASTIM â„¢), after X-ray -chemotherapy, in Germany. The Company is planning a combined Phase IIa clinical trial in patients with advanced NSCLC receiving ENKASTIM â„¢ and PD (L) -1 checkpoint inhibitors, post standard of care, in the United States. Alphageneron is also planning a Phase I association clinical trial for metastatic colorectal cancer with Allogeneic Donor Genetically Modified NK Cell Therapy (ANKASTIM â„¢) in the United States.

Dated:

Monday, January 28, 2021

Time:

12 p.m. – 1 p.m. EDT

To register for this virtual event, click www.roth.com/healthcareprivateday or please contact Gerald Roger, c / o Trinity Capital Advisers Tel. 347-730-5108, or by email at [email protected]

About Alphageneron

Alphageneron Pharmaceuticals Inc., develops targeted autologous and allogeneic natural killer cells (“NK cells”), chimeric antigen receptor (“CAR”) NK cells, NK Cell Engager agents and drug conjugated antibodies, combined with Checkpoint inhibitors and supported by Diagnostics. The company’s leading autologous clinical therapy, called ENKASTIM, designs the patient’s NK cells to target a novel cancer biomarker, a membrane form of heat shock protein 70 (Hsp70). The Hsp70 membrane is strongly expressed by a wide range of cancers, not strongly on normal cells. Patients are first screened with our companion diagnostic (AP-CDx), an ELISA blood test that measures the levels of membrane-bound Hsp70 exosomes with a simple blood test. A phase I clinical trial involving twelve (12) patients was conducted in Germany, with metastatic colorectal cancer and non-small lung cancer (NSCLC) receiving our autologous NK cell therapy, called ENKASTIM, after standard of care (SOC) has demonstrated safety and signs of efficacy. A phase IIa (randomized, controlled) clinical trial involving fourteen (14) patients with advanced NSCLC (stage IIIb) was conducted in Germany, in the treated group of seven (7) patients who received ENKASTIM after radiochemotherapy , five (5) patients had clinical benefit including complete response and partial response (71%). Preclinical animal studies using allogeneic donor NK cell therapy (ANKASTIM â„¢) against various cancers have demonstrated significant destruction of cancer NK cells. We are developing NK Hsp70 cell accelerators and antibody-drug conjugates to treat cancer. Alphageneron is also developing allogeneic induced pluripotent stem cells (iPSC) from CAR-modified NK cells (CAR NK) to an undisclosed target.

The statements contained in this message which are not based on historical or current facts and constitute “forward-looking statements” within the meaning of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results, events or developments to differ materially from future results, events or developments expressed or implied by such forward-looking statements. Although Alphageneron believes that the expectations conveyed by forward-looking statements are reasonable based on information available to it at the date of such statements, no assurance can be given as to future results, approvals or achievements. In light of these uncertainties, readers are cautioned not to place undue reliance on these forward-looking statements and should assume that the Company has no obligation to update any forward-looking statements, except as required by applicable law otherwise.


Previous A month later, authorities have no new information to share on who killed Jasmyn Beatty
Next "We'll clean this up if it's the last thing I do:" The president of the pension council is satisfied with the progress report of the audit